RCUS vs ZLAB
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RCUS · Arcus Biosciences$18.28 ▲ 3.34%
ZLAB · Zai Lab$25.48 ▲ 12.74%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RCUS -6.1%
- ZLAB +16.4%
Head to head
| Metric | RCUS | ZLAB |
|---|---|---|
| Price | $18.28 | $25.48 |
| Change today | ▲ 3.34% | ▲ 12.74% |
| Market cap | $2.63B | $2.87B |
| Return, 3 months | -36.4% | +8.1% |
| Return, year to date | -23.3% | +44.4% |
| Return, 1 year | -5.3% | +16.3% |
| P/E (TTM) | -5.0 | -14.2 |
| P/B | 7.4 | 5.1 |
| P/E percentile vs own 5y | 51st | 18th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -74.4% | -3.3% |
| Net profit growth (YoY) | – | -24.8% |
| Gross margin | – | 56.5% |
| Operating margin | -415.4% | -57.4% |
| Net margin | -393.2% | -41.9% |
| Return on equity | -90.8% | -26.9% |
| Analyst target vs. price | +122.6% | +54.4% |
| Analyst buy share | 73% | 100% |
| RSI (14) | 37 | 58 |
| 30-day volatility | 82.7% | 68.7% |
| Max drawdown, 1 year | -44.0% | -39.1% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ZLAB is the largest of the group by market value.
- ZLAB has returned the most over the past year.
- ZLAB carries the lowest trailing P/E.
- ZLAB is growing revenue fastest.
- ZLAB keeps the most profit per dollar of sales.
- ZLAB has been the calmest stock over the last 30 days.